This company listing is no longer active
KA6N Stock Overview
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Karo Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.44 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$4.57 |
| Beta | 0.10 |
| 1 Month Change | 0.37% |
| 3 Month Change | -1.81% |
| 1 Year Change | -2.68% |
| 3 Year Change | 48.31% |
| 5 Year Change | 40.68% |
| Change since IPO | -99.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| KA6N | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.7% | -2.5% | -2.6% |
| 1Y | -2.7% | -15.6% | 6.9% |
Return vs Industry: KA6N exceeded the German Pharmaceuticals industry which returned -8.8% over the past year.
Return vs Market: KA6N exceeded the German Market which returned -16.6% over the past year.
Price Volatility
| KA6N volatility | |
|---|---|
| KA6N Average Weekly Movement | 1.9% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: KA6N has not had significant price volatility in the past 3 months.
Volatility Over Time: KA6N's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 225 | Christoffer Lorenzen | www.karopharma.com |
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands.
Karo Pharma AB (publ) Fundamentals Summary
| KA6N fundamental statistics | |
|---|---|
| Market cap | €15.95b |
| Earnings (TTM) | -€189.85m |
| Revenue (TTM) | €3.47b |
0.0x
P/S Ratio0.0x
P/E RatioIs KA6N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KA6N income statement (TTM) | |
|---|---|
| Revenue | SEK 3.47b |
| Cost of Revenue | SEK 1.50b |
| Gross Profit | SEK 1.96b |
| Other Expenses | SEK 2.15b |
| Earnings | -SEK 189.85m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 56.67% |
| Net Profit Margin | -5.48% |
| Debt/Equity Ratio | 104.8% |
How did KA6N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/27 17:02 |
| End of Day Share Price | 2022/11/24 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Karo Pharma AB (publ) is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Lindström | ABG Sundal Collier |
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Mats Liss | Kepler Cheuvreux |